Carregant...
Current status of immunological approaches for the treatment of prostate cancer
PURPOSE OF REVIEW: The recent Food and Drug Administration approval of sipuleucel-T for metastatic castration-resistant prostate cancer and of the anticytotoxic T-lymphocyte antigen 4 antibody (Ipilimumab) for metastatic melanoma has led to a renewed interest in immunotherapy for prostate and other...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4124631/ https://ncbi.nlm.nih.gov/pubmed/20179598 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOU.0b013e3283381793 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|